SUMMIT THERAPEU/S (NASDAQ:SMMT) Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC decreased its stake in SUMMIT THERAPEU/S (NASDAQ:SMMT) by 4.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 175,500 shares of the company’s stock after selling 7,660 shares during the period. Acadian Asset Management LLC owned about 1.27% of SUMMIT THERAPEU/S worth $321,000 at the end of the most recent quarter.

Shares of NASDAQ:SMMT opened at $1.24 on Friday. The firm has a market capitalization of $17.58 million, a PE ratio of 1.48 and a beta of 1.45. SUMMIT THERAPEU/S has a one year low of $1.10 and a one year high of $13.39.

SUMMIT THERAPEU/S (NASDAQ:SMMT) last issued its quarterly earnings results on Wednesday, March 27th. The company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.13). SUMMIT THERAPEU/S had a return on equity of 27.08% and a net margin of 24.32%. The company had revenue of $0.66 million during the quarter, compared to the consensus estimate of $4.44 million. On average, equities research analysts expect that SUMMIT THERAPEU/S will post -1.23 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. Oppenheimer reissued a “hold” rating on shares of SUMMIT THERAPEU/S in a report on Thursday, March 28th. HC Wainwright set a $2.00 price target on shares of SUMMIT THERAPEU/S and gave the stock a “buy” rating in a report on Thursday, March 28th. Finally, Zacks Investment Research lowered shares of SUMMIT THERAPEU/S from a “buy” rating to a “hold” rating in a report on Saturday, February 23rd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $2.70.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at


Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Featured Article: Understanding Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for SUMMIT THERAPEU/S (NASDAQ:SMMT)

Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with's FREE daily email newsletter.